HALO — Halozyme Therapeutics, Inc.
$100.27
$-0.40 (-0.40%)
Halozyme Therapeutics, Inc., a biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.
Market Cap
$11.43B
Forward P/E
9.5x
52-Week Range
N/A
HALO Price History
Revenue vs. Net Income
$1.4B
Revenue · FY2025
Annual. Net margin is shown under each year.
Free Cash Flow
$357M
FCF · FY2025
Annual. FCF margin is shown under each year.
Return on Capital Employed (ROCE)
20.7%
ROCE · FY2025
Annual. Green above 0%, red below. Dashed line marks the 15% compounder threshold.
Total Assets vs. Total Liabilities
1.0x
Assets ÷ liabilities · FY2025
Annual. What the company owns against what it owes. Assets ÷ liabilities is shown under each year.
CapEx as % of Revenue
21.1%
CapEx · FY2025
Annual. Green at or under the 5% maximum target, red above it.
Shares Outstanding
-4.3%
Net buyback · FY2025
Annual diluted shares. Under each year: the change on the previous year (green = buyback, amber = dilution).
